Skye Bioscience Statistics

Total Valuation

Skye Bioscience has a market cap or net worth of $90.41 million. The enterprise value is $23.19 million.

Market Cap	90.41M
Enterprise Value	23.19M

Important Dates

The next estimated earnings date is Friday, March 7, 2025, after market close.

Earnings Date	Mar 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Skye Bioscience has 30.34 million shares outstanding. The number of shares has increased by 537.83% in one year.

Current Share Class	30.34M
Shares Outstanding	30.34M
Shares Change (YoY)	+537.83%
Shares Change (QoQ)	+0.39%
Owned by Insiders (%)	3.05%
Owned by Institutions (%)	45.26%
Float	15.06M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.19
P/TBV Ratio	1.19
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 14.19, with a Debt / Equity ratio of 0.00.

Current Ratio	14.19
Quick Ratio	11.99
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-14.58

Financial Efficiency

Return on equity (ROE) is -54.82% and return on invested capital (ROIC) is -35.95%.

Return on Equity (ROE)	-54.82%
Return on Assets (ROA)	-30.39%
Return on Invested Capital (ROIC)	-35.95%
Return on Capital Employed (ROCE)	-31.11%
Revenue Per Employee	n/a
Profits Per Employee	-$1.93M
Employee Count	11
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Skye Bioscience has paid $10,071 in taxes.

Income Tax	10,071
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -50.08% in the last 52 weeks. The beta is 1.88, so Skye Bioscience's price volatility has been higher than the market average.

Beta (5Y)	1.88
52-Week Price Change	-50.08%
50-Day Moving Average	2.98
200-Day Moving Average	5.71
Relative Strength Index (RSI)	48.34
Average Volume (20 Days)	226,002

Short Selling Information

The latest short interest is 1.80 million, so 5.92% of the outstanding shares have been sold short.

Short Interest	1.80M
Short Previous Month	1.90M
Short % of Shares Out	5.92%
Short % of Float	11.94%
Short Ratio (days to cover)	5.76

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-23.62M
Pretax Income	-42.28M
Net Income	-21.24M
EBITDA	-23.46M
EBIT	-23.62M
Earnings Per Share (EPS)	-$0.72

Full Income Statement

Balance Sheet

The company has $67.41 million in cash and $190,994 in debt, giving a net cash position of $67.22 million or $2.22 per share.

Cash & Cash Equivalents	67.41M
Total Debt	190,994
Net Cash	67.22M
Net Cash Per Share	$2.22
Equity (Book Value)	75.80M
Book Value Per Share	2.50
Working Capital	74.18M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$20.91 million and capital expenditures -$1.56 million, giving a free cash flow of -$22.47 million.

Operating Cash Flow	-20.91M
Capital Expenditures	-1.56M
Free Cash Flow	-22.47M
FCF Per Share	-$0.74

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Skye Bioscience does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-537.83%
Shareholder Yield	-537.83%
Earnings Yield	-23.49%
FCF Yield	-24.85%

Analyst Forecast

The average price target for Skye Bioscience is $18.67, which is 526.51% higher than the current price. The consensus rating is "Buy".

Price Target	$18.67
Price Target Difference	526.51%
Analyst Consensus	Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-10.49%

Stock Forecasts

Stock Splits

The last stock split was on September 8, 2023. It was a reverse split with a ratio of 0.004:1.

Last Split Date	Sep 8, 2023
Split Type	Reverse
Split Ratio	0.004:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	2